title: Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study.
abstract: OBJECTIVE
  This study aimed to assess the role of tadalafil, a phosphodiesterase type 5 inhibitor (PDE5-I), in recovery of lower urinary tract symptoms (LUTS) after robot-assisted radical prostatectomy (RARP).
  
  
  METHODS
  All patients treated with RARP between October 2010 and August 2013 were enrolled in this retrospective study on prospectively collected data. Patients were retrospectively divided into groups according to postoperative treatment: patients taking tadalafil twice weekly from 1 month to 6 months after RARP, and patients not taking tadalafil. The International Prostate Symptom Score (IPSS), the Overactive Bladder Symptom Score (OABSS) and urinary continence (UC) were assessed preoperatively (2 days before RARP) and at 1, 3, 6, 9 and 12 months after RARP.
  
  
  RESULTS
  There was no difference in the overall IPSS score between the groups. At 6 and 9 months, the IPSS storage symptom scores were significantly lower in patients taking tadalafil than in patients not taking tadalafil. In patients with overactive bladder (OAB) before RARP (n = 22), no differences in the total scores of OABSS were seen between patients taking tadalafil and patients not taking tadalafil. On the other hand, in non-OAB patients before RARP (n = 68), at 3, 6 and 9 months, the total scores of OABSS were significantly lower in patients taking tadalafil than in patients not taking tadalafil. No differences in UC rates after surgery were seen between the groups.
  
  
  CONCLUSIONS
  Postoperative tadalafil treatment may be temporarily effective for the recovery of the IPSS storage symptom scores and OABSS.
authors.affiliation: a Department of Urology , Tottori University Faculty of Medicine , Yonago , Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Honda
authors.affiliation: a Department of Urology , Tottori University Faculty of Medicine , Yonago , Japan.
authors.forename: Bunya
authors.initials: B
authors.lastname: Kawamoto
authors.affiliation: a Department of Urology , Tottori University Faculty of Medicine , Yonago , Japan.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Morizane
authors.affiliation: a Department of Urology , Tottori University Faculty of Medicine , Yonago , Japan.
authors.forename: Katsuya
authors.initials: K
authors.lastname: Hikita
authors.affiliation: a Department of Urology , Tottori University Faculty of Medicine , Yonago , Japan.
authors.forename: Kuniyasu
authors.initials: K
authors.lastname: Muraoka
authors.affiliation: a Department of Urology , Tottori University Faculty of Medicine , Yonago , Japan.
authors.forename: Takehiro
authors.initials: T
authors.lastname: Sejima
authors.affiliation: a Department of Urology , Tottori University Faculty of Medicine , Yonago , Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takenaka
mesh_terms: D000368:Aged; D006801:Humans; D008137:Longitudinal Studies; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D011182:Postoperative Care; D011468:Prostatectomy / Q000534:rehabilitation*; D011471:Prostatic Neoplasms / Q000601:surgery*; D012189:Retrospective Studies; D065287:Robotic Surgical Procedures / Q000534:rehabilitation; D000068581:Tadalafil / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000503:physiopathology; D014549:Urinary Incontinence / Q000503:physiopathology
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil
keywords: Lower urinary tract symptoms; penile rehabilitation; phosphodiesterase type 5 inhibitor; prostate cancer; robot-assisted prostatectomy